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ABSTRACT
T lymphocytes represent an important part of adaptive immune system undertaking different
functions to regulate immune responses. CD4+ T cells are the most important activator cells in
inflammatory conditions. Depending on the type of induced cells and inflamed sites, expression
and activity of different subtypes of helper T cells are changed. Recent studies have confirmed the
existence of a new subset of helper T lymphocytes called Th9. Naive T cells can differentiate into Th9
subtypes if they are exposed simultaneously by interleukin (IL) 4 and transforming growth factor β
and also secondary activation of a complicated network of transcription factors such as interferon
regulatory factor 4 (IRF4) and Smads which are essential for adequate induction of this phenotype.
Th9 cells specifically produce interleukin 9 and their probable roles in promoting intestinal inflam-
mation are being investigated in human subjects and experimental models of ulcerative colitis
(UC). Recently, infiltration of Th9 cells, overexpression of IL-9, and certain genes associated with
Th9 differentiation have been demonstrated in inflammatory microenvironment of UC. Intestinal
oversecretion of IL-9 protein is likely to break down epithelial barriers and compromise tolerance to
certain commensal microorganismswhich leads to inflammation. Th9 pathogenicity has not yet been
adequately explored in UC and they are far from being considered as inflammatory cells in this milieu,
therefore precise understanding the role of these newly identified cells in particular their potential
role in gut pathogenesis may enable us to develop novel therapeutic approaches for inflammatory
bowel disease. So, this article tries to discuss the latest knowledge on the above-mentioned field.
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GATA Family of transcription factors bind to “GATA”
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CONTACT Professor Hedayatollah Shirzad shirzad@yahoo.com Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord
University of Medical Sciences, Shahrekord, Iran.
Color versions of one or more of the ﬁgures in the article can be found online at www.tandfonline.com/iiri.
OX40 Tumor necrosis factor receptor superfamily
member 4
PU1 An ETS family transcription factor
ROS Reactive oxygen species
RSV Respiratory syncytial virus
STAT Signal transducer and activator of transcription
TCR T cell receptor
TGF-β Transforming growth factor beta
TLR Toll-like receptor
TNBS Trinitrobenzenesulfonic acid
Tregs Regulatory T cells
TSLP Thymic stromal lymphopoietin
UC Ulcerative colitis
1. Introduction
Effective immunologic responses are strongly depen-
dent on the accurate induction of T cells. By expressing
CD40 ligand, they provide required signals for clonal
©  Taylor & Francis
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expansion of B cells, immunoglobulin switching, and
antibody production.1 They also regulate innate immu-
nity through affecting macrophages and neutrophils,
create memory T cell response, and manage inflamma-
tory responses to pathogens.2 However, uncontrolled T
cell response can cause pathological alterations which
may leads to allergy and autoimmunity.3 A naive T
cell in the presence of interleukin (IL)-4 and trans-
forming growth factor (TGF)-β secretes IL-9, which
drives cellular responses toward the differentiation of
a novel characterized type of CD4+ cells named Th9.4
The existence of Th9 cells and their roles as novel
players in gut immunity have been confirmed in a
number of studies. For example, compromised tissue
integrity and sustained inflammatory responses during
flare of ulcerative colitis (UC) in colon are related to
IL-9 production by Th9 cells.5,6 Tight junction pro-
teins as principal components of intercellular adhesion
mechanisms are important molecules, which maintain
intestinal tissue integrity and prevent luminal antigens
from being exposed to inflammatory cells present in
lamina propria.7 Recent studies have also shown some
alterations in expression of these proteins by Th9-derived
IL-9 that result in further gut inflammation. This arti-
cle tries to discuss the harmful roles of Th9 cells in
the gut.
2. Various CD4+ cells are distinctively
differentiated
Multiple immune responses of the host subsequent to
pathogen’s crossing the innate immunity barriers are
dependent on the appropriate function of T lymphocytes.
According to their identifying markers and activities,
T cells are divided into three major classes as follows:
CD8+ T lymphocytes that are cytotoxic or killer cells
and are known to be involved in response to tumor,
metastatic cells, and viral infections.8 Regulatory T cells
(Tregs) that play a significant role in suppressing inflam-
matory responses, inducing immunological tolerance,
and regulating immune responses to prevent autoimmu-
nity through secretion of certain immunomodulatory
cytokines such as IL-10, TGF-β , and IL-35 or via cell-cell
contact.9,10 CD4+ helper T cells that are major play-
ers in inflammatory milieu contributing to antibody
production, regulating innate immunity, and inducing
immunologic memory. Predominant types of these cell
lineages including Th1, Th17, Th22, Th9, Th2, and TFH,
are developed through T cell receptor (TCR) signaling
and being affected by various cytokines and transcription
factors (Figure 1).11–13
3. Th9 cells: Signaling pathways and cytokine
profile
3.1. Characteristics and secretion sources of
interleukin 9
IL-9 is amultifunctional cytokine and themost important
source of IL-9 is Th9 lymphocytes. Therefore, they are
most probably involved in the responses associated with
increased IL-9 level during the process of inflammatory
damages caused by immune system hyperactivity.22–24
Although IL-9 is structurally different from lympho-
cytes growth factors, it was first identified and cloned
as a growth factor of murine mast cells and T cells (T
cell growth factor III) in 1980.23,25 IL-9 is a cytokine
with a common gamma-chain receptor similar to IL-4,
−2, and −15, and upon binding to its receptor on target
cells induces a signal through activation of janus kinase
1 (JAK1) and JAK3, creating a dimer between signal
transducer and activator of transcription 3 (STAT3),
STAT5, and STAT1.26–28 The alpha subunit of IL-9 recep-
tor contains WSXWS and BOX motifs and therefore is
considered as a member of hematopoietin family.22 The
encoding gene of the protein of 144 amino acids is local-
ized to chromosome 5 in human and chromosome 13 in
mouse.29,30 Th9 cells secrete abundant amounts of IL-9,
but no specific and definite transcription factor has yet
been defined for their complete differentiation.31 First,
because of increased release of IL-9 from Leishmania-
infected murine Th2 cells, it was thought that IL-9 was
generated only by Th2 cells therefore, its role has been
investigatedmainly in Th2-related pathologies.32 It seems
that in different immunological conditions, various fac-
tors impact induction of IL-9.4 Via the simultaneous
effects of IL-4 and TGF-β on naive T cells, their down-
stream signaling proteins such as GATA3, interferon
regulatory factor 4 (IRF4), STAT6, and PU1 are being
activated and induce IL-9 promoter transcription.33 PU1-
deficient mice exhibit potent inhibitory responses against
the IL-9-dependent allergic airway inflammation. Such
mice have a normal Th2 response despite having low
amounts of IL-9. This indicates that PU1 play a critical
role inTh9development.17 Evidence remains inconsistent
on factors that physically interact to activate IL-9 gene. In
some allergic responses such as lung inflammation and
certain anaphylactic conditions, Th2 and Th9 cells are
deeply proliferated.34–36 Th17 cells that are induced in
IL-6 and TGF-β containing environment, can generate
IL-9 under certain conditions, however, IL-23 which pro-
motes induction of Th17 cells was reported to decrease
IL-9 generation. This indicates that IL-9 expression by
Th17 completely depends on types of signals in inflam-
matory environment and does not occur constantly.37,38
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Figure . Diﬀerentiationpathways of CD+ T cells. Antigenpresenting cells such asdendritic cells andB lymphocytes uptake antigens from
the environment and present to naïve T cells. Depending on the type of antigens, cytokines released in the environment and activation of
transcription factors, various types of CD+ cells are induced and interact with diﬀerent cell types and drive inﬂammatory responses with
respect to related proteins and chemokine receptors.–
In certain autoimmunities, such as experimental autoim-
mune encephalomyelitis (EAE) and type I diabetes, IL-9
is produced by Th17 phenotype.39 During EAE, IL-9
plays two different functions. It suppresses EAE-induced
inflammation by influencing Tregs function but intensi-
fies inflammatory mediators through affecting mast cells
and Th17 cells in an autocrine manner.37,38,40–42 In type I
diabetes, an autoimmune disease with Th17 dominancy,
the role of IL-9 has not yet been explained.43 Current
evidence on secretion of IL-9 by Tregs are inconsistent.
Although coexpression of forkhead box P3 (FOXP3) and
IL-9 has been observed in murine T cells in vivo, it has
not yet been determined whether FOXP3-expressing T
cells can generate IL-9 or not.44 IL-9 is an activator of
human mast cell progenitors. As crucial regulators of
innate immunity, mast cells expresses pattern recognition
receptors like Toll-like receptor (TLRs) to recognize
pathogen-associated molecular patterns and also are
capable of producing IL-9 protein in response to stem cell
factor, IL-10 and IL-3.45,46 By expressing IL-9 receptors,
they can be activated by IL-9 in an autocrine manner and
also can pathologically release this protein during allergic
diseases such as asthma and allergic rhinitis.47,48 Mucosal
mast cells are dominant secretors of IL-9 in experimental
models of intestinal food allergy.45 Although IL-9 is first
known as a growth factor of mast cells that was named
P40, they can generate IL-9 in response to lipopolysac-
charide (LPS) and IL-1 through nuclear factor kappa
B (NF-κB) activation.49 In addition, there are some
evidences indicating that histamine and IL-1β induce
IL-9 secretion from murine bone marrow-derived mast
cells.50,51 Interestingly, remarkable infiltration of both
chymase+ and trypase+ mast cells were observed by
immunohistochemical staining of chronic UC lesions
and it is stated that mast cells are the major source of
several inflammatory mediators which can increase
intestinal permeability and inflammation during gut-
related pathologies.52,53 There are reports that murine
naïve natural killer T cells can also secrete IL-9 in the
presence of IL-2. However, due to certain similarities in
signaling pathways between IL-9 and IL-4, −5, and IL13,
these proteins are secreted from these cells following IL-9
induction.54 In natural killer cell (NKT)-CD1d deficient
mouse, allergic airway inflammation leads to decreased
production of IL-9 and decreased infiltration of mast
cells in the lung, which confirms NKT’s ability to produce
IL-9 in vivo.55 As a growth factor, IL-9 can cause NKTs
transformation into nasal NKT cells lymphoma. In tissue
sections of patients with nasal NKT cells lymphoma,
the trafficking of IL-9 generating NKTs was reported.56
Innate lymphoid cells are recently defined subtypes,
which contribute to both innate and adaptive immune
responses. They have diverse distribution in lymphoid
andmucosal tissues and are involved in tissue remodeling
and homeostasis. Type 2 innate lymphoid cells (ILCs)
which are more characterized by Th2-like responses are
mainly induced by effects of IL-25, IL-33, thymic stromal
lymphopoietin (TSLP), IL-4, IL-7, and IL-9.57 ILC2s
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are also important regulators of epithelial responses in
acute lung allergy which their effective induction in
such condition is mainly dependent on IRF4 and IL-9.58
During Th2-mediated intestinal inflammation, IL-33 is
produced by damaged epithelial cells which affects ILC2s
to release more IL-9 and finally more eosinophil recruit-
ment, mucus secretion, and mastocytosis in response to
IL-5 and IL-13, respectively.59 We have given a snapshot
of different sources of IL-9. Obviously, this protein plays
significant roles in different diseases via its widely vari-
ous functions. Now, we touch on cytokines, genes, and
signaling pathways involved in Th9 development.
3.2. Differentiation pathways of Th9 cells
IL-4 and TGF-β activate two distinct pathways in T cells.
The former causes transcription of GATA3 and STAT6
genes that leads to cell response toward Th2, and the lat-
ter activates FOXP3 and inducesTregs differentiation.60,61
The simultaneous effects of these two cytokines on T
cells lead to generation of IL-9 and induction of Th9
phenotype.62 It has not yet been definitely determined
which transcription factors physically interact and bind
to IL-9 promoter. Different studies have reported incon-
sistent findings on this issue that will be distinctively
quoted.Multiple proteins are considered as IL-4 andTGF-
β downstream signals that contribute to amplification of
IL-9 promoter as a complicate network63–65 (Figure 2).
... Positive regulators
As shown in Figure 2, all of these proteins contribute
somehow to the induction of Th9 cells. Here, they will be
discussed individually. IRF4 is the first factor of interest
whose key role has been demonstrated in increasing
transcription of IL-9 gene in T lymphocytes. Phospho-
rylation of STAT6 occurs following IL-4’s binding to
its receptor, and then IRF4 is activated and binds to
IL-9 gene.66,67 However, appropriate induction of other
cells such as Th17 and Th2 depends on the presence
of this factor.68,69 IRF4-deficient mouse cannot induce
IL-9-secreting T cells, and also silencing of IRF4 mRNA
by relevant SiRNA prevents development of Th9 phe-
notype and activation of IL-9 promoter.70 GATA3 is
the other factor that is activated by STAT6 and causes
destruction of T-Bet and FOXP3. It has not yet been
determined whether GATA3 binds to the IL-9 gene
directly or not.30 After TGF-β binding to its receptor, a
factor called PU1 activates IL-9 promoter through bind-
ing to IRF4.71 PU1 is an ETS family transcription factor
whose increased expression has been reported in certain
Th9-dependent pathologies such as allergic inflammation
and inflammatory bowel disease (IBDs).17,72 Although
the signaling pathways of Th9 and Th2 cells are partly
similar, increased expression of PU1 causes downregula-
tion in Th2 response. This indicates that differentiation
of these two subsets may be completely separated under
different conditions.73 Effects of PU1 on inducing Th9
cells is due to histone modifications caused by this factor,
and T cells that do not have such factor are not able
to generate IL-9 in IL-4 and TGF-β-containing culture
media. As with IRF4, silencing of PU1-related mRNA
by SiRNAs leads to decreased response of Th9 and also
inability to generate IL-9.17 Other factors which become
activated following TGF-β ’s effect on T cells are SMADs
molecules that potentially play a role in activating IRF4.
A study with an experimental model of asthma demon-
strated that SMAD2 and SMAD3 bound to IRF4 directly
and exerted exponential effects on IL-9 production
Figure . A complex set of cytokines and transcription factors involved in Th phenotype induction and IL- production by murine and
human lymphocytes. Interactions among these factors in diﬀerent diseases to bind to the gene and amplify IL- mRNA varies, which
represents the plasticity of T helper cells and dependency of their diﬀerentiation on the types of inﬂammatory responses involved in the
environment.
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by T cells. This study, inconsistent with the previous
studies, demonstrated that instead of PU1, SMAD2 and
SMAD3 directly bound to IRF4 via MH1 and MH2
domains and therefore activated IL-9 gene.74 Differen-
tiation of Th9 cells seems to be varies under different
conditions depending on the involved transcription fac-
tors and the way they get activated. Besides that, TSLP,
nitric oxide, and IL-1β play important roles in activating
Th9 cells, such that increased expression of IL-9 has been
reported in response to such stimuli inmouse and human
T lymphocytes.75,76 In addition to the effects of IL-4 and
TGF-β on T cells, TCR signaling causes increase in
certain factors such as intracellular domains NFAT, AP1,
Notch1, and NF-κB that are likely to contribute to bind-
ing to the IL-9 gene promoter.77 Differentiation of Th9
cells and IL-9 secretion can even be dependent on type
I interferons and IL-21.78 It has been shown that basic
leucine zipper ATF-like transcription factor (BATF), as
an AP1 family transcription factor, can directly affect
Th9 induction, such that the IL-9-dependent secretion
of BATF is greater in atopic children’s T cells compared
to healthy children’s T cells. In addition, BATF-deficient
T cells cannot produce IL-9 through allergic responses
in the mouse model.79 In addition, engagement of TLR2
signaling in CD4+ T cells under Th9 differentiation
increased the expression of BATF and PU1, which are
crucial for IL-9 transcription.80 Recently a study indi-
cated that induction of IL-9 protein could be positively
dependent on transcription factor FOXO1 in coopera-
tion with IRF4. FOXO1 is a member of forkhead family
transcription factors which has been shown to promote
both Th9 and Th17 allergic responses through IL-9
induction.81 It has also been shown that nitric oxide can
positively impact on Th9 polarization and expression
of IRF4/STAT5 by increasing IL-4R and TGF-βR on
human and mouse CD4+ T cells. Accordingly, in an
ovalbumin (OVA)-induced airway inflammation, nitric
oxide synthase 2 (NOS2)-negative mice exhibited less
Th9 response in comparison with wild-type model.82
... Negative regulators
Th9 cells have been shown to considerably promote anti-
tumor activity in a pulmonary melanoma model through
a CCR6-dependent recruitment of specific CD8+ CTLs
in tumor tissue; however, Th9-related tumor suppression
can be promoted by a deficiency in histone deacetylase
SIRT1, which cooperates withmTOR-TAK1-HIF1α com-
plex in glycolysis pathway.83,84 SiRNA-related or conven-
tional inhibition of SIRT1 in human and mouse CD4+
T cells promoted both pathologic allergic responses and
antitumor activity by Th9 cells.83 The transcriptional
B cell repressor lymphoma 6 (BCL6), which is mainly
required for follicular helper T cell development, can
impair Th9 induction and IL-9 transactivation. Ectopic
expression of IFNγ , IL-2, and IL-21 in EAE results in
BCL6-dependent inhibition of IL-9 which can exacerbate
the disease symptoms.65,85 Also, it has been reported that
IFNγ can increase the expression of IL-27 by mast cells
through the activation of STAT1.86 As indicated before,
more pronounced Th9 response is significantly relate to
allergic lung inflammation. In an experimental model of
allergic lung failure, it was observed that cyclooxygenase
enzyme 2 was the main inducer of prostaglandins D2
and E2 which were the pivotal downregulators of Th9-
derived IL-9 through the inhibition of IL-17 receptor B.
In addition, Cox2-negative CD4+ T cells can consider-
ably express IL-9 protein in a culture media containing
IL-4 and TGF-β , which confirms the negative effects of
Cox2 on Th9 activation.87
4. Th9 cells: Infection and allergic responses
IL-9 and Th9 cells play significant roles in mucosal
immunogenicity throughout asthma-induced allergic
responses, airway inflammation, and allergic rhinitis.88
Genetically, chromosome 5, IL-9 and its receptor, and the
secretion rate of serum IgE are directly associated.89,90
The pathogenicity of IL-9 has been frequently demon-
strated in the mouse model of allergy such that inject-
ing mice with this protein has led to increased serum
IgE levels, eosinophils infiltration, and airway hyper-
responsiveness (AHR).91,92 In mouse aspergillosis, IL-9
causes such responses in transgenic state.93 In addition,
in experimental models of asthma, several factors such as
TSLP, tumor necrosis factor receptor superfamily mem-
ber 4 (OX40), TRAF6 ligase, BATF kinase, NIK, and
NF-κB are the stimulators of IL-9 promoter, and there-
fore play critical roles in activating Th9 cell-dependent
inflammatory pathways in these models.75,94–97 Goblet
cell metaplasia is also one of the IL-9 effects through-
out allergic inflammation which is associated with IL-
13 and the activation of hematopoietic cells.35 Anti-IL-9
antibody therapy in a mouse model of allergy alleviated
the symptoms, although allergic reactions and the infil-
tration of mast cells may occur even in the experimen-
tal model of asthma in transgenic mice in the absence of
the gene.98,99 In asthmatic patients, the secretion levels
of IL-9 and its receptor increase significantly.100 Besides
that, IL-9 can cause increase in mucus secretion, infil-
tration of eosinophils, mastocytes, and neutrophils, and
disruption of airway tissue collagenous structure.101 High
amounts of IL-9 have also been demonstrated in aller-
gic rhinitis, which is directly correlated with the infiltra-
tion rate of nasal eosinophilia.102 Recently, traces of Th9
cells and IL-9 have been reported in certain infections.
Regarding parasitic infections, evidence on IL-9 effects
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are inconsistent. Increase in IgG generation and bowel
hypermotility as well as effect on muscles to excrete the
parasite, the activation of tissue mastocytosis, and ulti-
mately increased activity of eosinophils to fight nema-
todes such asTrichinella andTrichurismuris are all depen-
dent on IL-9 and its protective effects. On the other
hand, blocking IL-9 by antibody in these models led
to opposite outcomes that confirm its effect on intesti-
nal clearance.103,104 In contrast, in mouse experimental
models of Giardia lamblia and Nippostrongylus brasilien-
sis infections, no effect was reported on defense mecha-
nisms against the parasites in the absence of IL-9, and they
were easily cleared of infection.105 Besides that, in mouse
model of schistosomiasis, it is noteworthy that granuloma
derived from Schistosomia eggs was formed even in the
absence of IL-9.106 In patients with alveolar echinococco-
sis, who are predisposed to acute liver damages, the secre-
tion rate of IL-9 and the expression of IRF4 and PU1 were
dramatically increased in peripheral blood mononuclear
cells (PBMCs) and inflamed liver tissues, which repre-
sents enhanced activity of Th9 cells in this condition.107
Certain effects of IL-9 have also been reported in viral
infections. Respiratory syncytial virus (RSV) is one of the
most common causes of viral infections in children that is
closely associated with asthma incidence and also causes
bronchitis or chronic inflammation of the bronchi.108 In
experimental model, increased IL-9 in RSV infection and
rapid clearance of the virus in case of blocking this pro-
tein were reported.109 Throughout infection with gram-
negative bacteria such as Pseudomonas, the symptoms
are relieved after injecting IL-9 to mice infected with
this bacterium, which is due to decrease in TNFα and
IFNγ , and increase in IL-10 secretion.110 In patients with
chronic mucocutaneous candidiasis (CMC), the levels of
IL-9 were decreased compared to healthy controls, which
indicates that Th1 and Th17 responses are dominant in
this milieu.111 Table 1 demonstrates the effects of IL-9 and
Th9 cells during certain infections.107,110,112–119
5. Th9 and intestinal inflammation
5.1. Intestinal tolerance: A unique feature
The digestive immune system is the evolutionary oldest
and the most sophisticated organ of the body, which
designed pivotal tolergenic mechanisms and a specific
cellular map to maintain the mucosal layers sterile and
separated from the luminal antigens that is estimated to
be 100 million microbial cells.120,121 Effective mucosal
homeostasis is mostly dependent on early encountering
to various microorganisms of normal flora and also
proper nutrition. For instance, early exposure to some
clostridium subtypes is necessary for accumulation of
CD4+CD25+ Tregs in the colon which have protec-
tive effects on IBDs. Accordingly, reduced clostridium
serotypes in IBD patients were observed.122–124 Intraep-
ithelial lymphocytes (IELs) are other important cells
participated in colon homeostasis which are involved
in mucosal defense and wound repair and their differ-
entiation is associated mainly with aryl hydrocarbon
receptors. It has been reported that a cruciferos
vegetables-depleted nutrition negatively affects Ahr
and IELs polarization leads to invasion of pathogens and
intensified inflammatory responses.125 Also deficiency
in vitamins A and D, tryptophan, and milk-derived
taurocholic acid all are related to Tregs dysfunction and
impaired antimicrobial peptides which may result in
epithelial damage and intestinal inflammation.126,127
Goblet cells are the main source of glycosylated mucins
which construct two distinct mucosal layers on epithe-
lium surface and restrict the direct adhesion of microbial
pathogens to the epithelium. Severe functional defects of
goblet cells specially MUC2 gene have been reported in
UC patients.128–130 Paneth cells are other protective cells
that play an important role in maintaining hemostasis
in small intestine through the secretion of antimicrobial
peptides. Genetical defects in autophagy-related genes
NOD2, ATGL16, andXBP1, which are severely associated
with Crohns disease incidence, can impair the release of
antimicrobial proteins from paneth cells.120,131 As a sec-
ondary source of IL-9, NKT cells recruit to inflammation
sites in response to CXCL16 chemokine and produce
IL-13, which promotes UC pathogenesis. It has been
reported that intestinal colonization of a neonatal mouse
with microbial normal flora inhibits infiltration of iNKT
cells and protects from oxazolone-induced colitis.132,133
5.2. Th9 and experimental ulcerative colitis
Recent studies on mouse models of IBD and patients
with IBD especially UC, demonstrated that the pro-
duction of IL-9 and Th9-related transcription factors
are increased.6,72,134,135 Here we discuss how these cells
potentially exhibit pathological activity through the
inflammatory responses in the large intestine. Crohn’s
disease and UC are two important types of IBD that
cause inflammation of the gastrointestinal tract lining
tissues due to genetical predisposition and effects of
environmental factors. Although these diseases share
certain characteristics, they are completely different in
terms of pathophysiology, the types of cell response, and
genes involved in the incidence of the disease.136 Crohn’s
disease causes deep inflammation alongside sporadic (but
not continuous) involving of submucosa throughout the
whole gastrointestinal tract from the mouth to the anus,
while UC causes superficial inflammation restricted
INTERNATIONAL REVIEWS OF IMMUNOLOGY 7
Table . Pathologic and protective activity of Th cells in several microbial infections.
Type of infection Secretion sources of IL- Related eﬀects Ref.
Parasitic—Schistosoma
japonicum
Th cells-CDS+ cells-NKT
cells-yo T cells
Promote liver failure and hepatic damages 
Parasitic—Trichinella spiralis Th cells-Th cells Promote bowel mastocytosis and intestinal permeability leading
to parasite expulsion

Parasitic—Trichuris muris Th cells-Th cells Increase muscle contraction and goblet cells hyperplasia and
promote worm expulsion

Parasitic—H. polygyrus CD+ T cells (CTLA dependent) Single infection: low amount, decreased mastocytosis in mice
coinfection with T. spiralis: high amount, increased mast cells
hyperplasia and worm expulsion in mice
,
Parasitic—Strongyloides
stercolaris
Th cells Increase Ag-speciﬁc responses and protection in human patients ,
Parasitic—Giardia Iambiia,
Nippostrongylus brasiliensis
Th cells Complete parasite clearance even in absence of IL- ,
Parasitic—Echinococcus
mutilocularis
Th cells Increase parasite persistence in host in human patient ,,
Bacterial—Pseudomonas
aeruginosa
T cells Protective eﬀects through suppression of TNF-a and induction of
IL-

Bacterial—Chlamydia
muridarum
CD+ T cells No signiﬁcant eﬀect on Ab response and protection against lung
infection in mice

Viral—Coxsackievirus B CD+ and CD+ T cells Protective eﬀects—inhibited virus replication 
Viral—RSV CD+ T cells Increase mucus production and lung failure ,
Fungal—Candida albicans Th, Th cells General defect in IL- induction—protective eﬀects in CMC 
in the large intestine.137 In Crohn’s disease, Th1- and
Th17-related cytokines are involved, while in UC, Th2
responses are dominant.138 Due to the similarity and
dependence of Th2 and Th9 responses on each other,
increased IL-9 and Th9 cells represents a component
of UC pathogenesis. In other words, these cells do not
receive their required signals to completely differenti-
ate in Crohn’s disease inflammatory milieu. First, we
touch on evidence about the presence of Th9 cells in
the experimental models of IBD. In mouse model of
oxazolone-induced colitis where Th2 responses are dom-
inant as with human colitis, the gene expression of the
IL-9 in the inflamed intestinal tissue and CD4+ cells in
the spleen are increased compared to wild-type model. In
this model, immunohistochemical analysis confirmed the
presence and increased frequency of mucosal CD4+IL-
9+ cells. Although the production of small amounts of
IL-9 by innate lymphoid cells, CD117+ mast cells, and
CD11c+ cells has been reported, Th9 lymphocytes are
the most important source of this protein in oxazolone-
induced colitis.105 After rectal injection of oxazolone
and inducing intestinal inflammation in mice, Gerlach
et al. induced IL-9 deficiency in mice via two methods
as follow: using anti-IL-9 antibody and inducing genetic
defect in producing this cytokine. In both models of IL-9
deficiency, histopathological investigations demonstrated
that inflammation was much lower compared to the
wild-type model according to weight loss, clinical scores
calculated by high-resolution miniendoscopy, and reac-
tive oxygen species (ROS) bioluminescence evaluation.
These evidences are indicative of the effective role of IL-9
in regulating intestinal inflammatory responses in this
model. Inducing deficiency in PU1, a critical factor of Th9
induction in thismodel, caused decrease in the expression
of IL-9 and Th2 cytokines and significantly decreased the
disease symptoms. Increased expression of the IL-9 recep-
tor on the Epcam+ intestinal epithelial cells, also confirms
IL-9 activity against the tolergenic property of this tissue.6
In both patients with UC and experimental model of this
disease, pathogenic changes were induced by IL-9 in the
intestinal epithelial barriers and tight junction proteins.
In oxazolone-induced colitis where Th2 response is dom-
inant, expression of intestinal tissue-permeable proteins
such as claudins 1 and 2 increases, but in contrast, claudin
3 and occludin that increase the inhibitory activity of lin-
ing barriers significantly, were not changed. Bacterial
translocation and fluorescein isothiocyanate-dextran
effect on decreased permeability of the intestinal tissue
lining membrane, demonstrated that the permeability of
these membranes to many antigens decreased if the IL-9
was eliminated.6 Through using organoid cell culture,
creating three-dimensional crypts of the intestine, and
exerting IL-9’s effect on them, a study reported that IL-9
caused disruption in tissue remodeling mechanisms and
cell proliferation.6 Gerlach et al. conducted surgery to
induce injury in mouse intestinal tissue to investigate the
slowdown of tissue repair process and IL-9-dependent
wound healing. Two days after surgery, recombinant
IL-9’s effect showed that the duration of wound healing
increased considerably, which confirmed the potential
role of IL-9 in wound healing process.6 In an experimen-
tal model, namely trinitrobenzenesulfonic acid (TNBS)-
induced colitis, in which Th1 response is dominant as
with human Crohn’s disease, in contrast to the former
model, IL-9 had no effect on the expression of claudin 2
but affected the expression of occludin and claudin 1. This
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indicates that in addition to IL-9, other factors regulate
the expression of these molecules in different inflamma-
tory conditions. In TNBS-induced colitis in wild-type and
IL-9 deficient mice, the rates of inflammation and weight
loss in IL-9 knockout mice were much lower than those
in wild-type mice. Besides that, goblet cell dysfunction,
wound induction, and mononuclear cells accumulation
were much less pronounced in IL-9 knockout model.
The immunofluorescence study of lamina propria cells
revealed increased frequency of PU1+CD4+ cells in the
wild-type model, representing that the expression of this
factor depends on the frequency of the Th9 cells and the
amount of IL-9 in this model.5 Real-time PCR, western
blotting, and study of the tight junction proteins expres-
sion in TNBS-induced colitis showed that unlike claudin
1, the expression of claudins 4 and 7, Jam-A, and occludin
increased in the IL9-deficient model compared to the
wild-type model. Inconsistency in findings on claudins
expression in the models of oxazolone and TNBS-
induced colitis is due to different dominant cell responses
of these two models, such that it can be argued that IL-9
and Th9 cells exhibit regulatory activity in the TNBS-
induced colitis model due to similarity of this condition
to Crohn’s disease and Th1/Th17 dominancy.5 Immuno-
histochemical analyses of another experimental model of
intestinal colitis that was induced by the effect of dextran
sodium sulphate (DSS), showed an increase in Th9 cells
expressing PU1 and CD3 markers. In addition, anti-IL-9
antibody treatment for 2 weeks caused relief of the disease
symptoms anddecreased the inflammatorymediators due
to decline in activated lymphocytes in the lamina propria
ofmouse intestine.139 Taken together, it can be argued that
although Th9 cells need different transcription factors to
differentiate in various inflammatory conditions, these
cells increase in CD4+ cells-related inflammation, dys-
function of the intestinal lining barriers, and tolergenic
dysfunction of epithelial cells by changing the expression
of tight junction proteins, through secretion of IL-9 in the
experimental models of IBDs especially UC (Figure 3).
5.3. Th9 clinical manifestations in UC
Imbalance between the effector cells and the
immunomodulatory cells is one of the most impor-
tant reasons for the incidence and intensification of
inflammatory responses particularly in gastrointestinal
diseases such as gastritis or peptic ulcers.140–143 Mean-
while, increased in T cells, such as Th17, and associated
upregulation of the expression of inflammatory media-
tors such as IL-6, IL-23, and IL-33 is one of the important
causes of different clinical presentations of Helicobacter
pylori-related infections in the stomach such as duo-
denal ulcers and gastritis.144–148 The role of helper T
Figure . Pathological eﬀects of IL- on expression of tight
junction proteins and tissue repair mechanisms leads to dysfunc-
tion of epithelial barriers and declined tolergenic nature of intesti-
nal tissue.
cells in producing inflammatory mediators has also been
demonstrated during IBD. For example, Th1 and Th17
cells in Crohn’s disease, and Th2 cells-related cytokines
such as IL-4 and IL-13 in UC are increased in expression
and function.149,150 Following the elimination of proteins
that maintain tight intercellular junctions, integrity of
epithelial cells will be compromised resulting in easy pass
of luminal antigens and subsequently intensification of
IBD-induced inflammatory responses. Different proteins
have been identified in regards to this issue such as IL-17
and IL-22.151–153 Here we discuss mainly on the role of
IL-9 and possibly Th9 cells in expediting inflammation
and the pathogenicity of IBDs. The role of these cells
have been studied in different diseases such as allergies,
certain autoimmune conditions such as lupus, and dif-
ferent infections as we already discussed.100,154 Studies
on patients with UC demonstrated an important role
for Th9 cells in UC pathogenesis. The study of gene-
expression levels of IL-9 alongside other inflammatory
cytokines such as IL-6 and IL-17A which are associated
with Th17 subtype, confirmed increased expression of
these genes in inflamed biopsies taken from the intestines
of UC patients. Interestingly, the expression level of IL-9
mRNAwas directly correlated with inflammation score.72
Additionally, two-color immunofluorescence staining on
tissue samples demonstrated an increase in the frequency
of mucosal CD3+IL9+ cells in such patients. IRF4 and
PU1 have positive effects on IL-9 expression in T cells in
the presence of TGF-β and IL-4 and have been known
as two main factors for the differentiation of Th9 cells.66
The gene-expression levels of these molecules increase in
patients with intestinal colitis and are directly correlated
with intensification of inflammation and disease symp-
toms.72 After culturing peripheral blood lymphocytes
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under necessary conditions to induce Th9 cells, 6% of
these cells secrete IL-9, and the coexpression of CD3,
IRF4, and IL-9 was reported in 25% of these cells. In
addition, the expression of the α4/β7 integrin on the IL-
9-generating lymphocytes increased in peripheral blood
of patients with UC, which indicates their homing ability
in the epithelial tissue of the large intestine. Furthermore,
flow cytometric analysis has shown increased expression
of IL-9 receptor on the polymorphonuclear leukocytes
of the peripheral blood in patients with UC compared
to controls. Finally, this study has demonstrated that the
resistance of polymorphonuclear cells (PMNs) to apop-
tosis with IL-9 is increased in a dose-dependent manner.
As a result, this protein can serve as a significant inducer
of antiapoptotic signals of peripheral blood mononuclear
cells in such patients.72 Immunohistochemical staining
of αEβ7 and α4β7 integrins on T lymphocytes revealed
a remarkable mucosal accumulation of such cells in IBD
patients. Therapeutically, targeting T cells homing in the
gut is a growing field of IBD treatment now. As reported,
intestinal recruitment of Th9 cells in IBD patients can
be inhibited using antibody blockade of αEβ7 integrin.
Etrolizumab monoclonal antibody to αEβ7 integrin
effectively blocked Th9 adhesion on mucosal E-cadherin
and MadCam1.155
6. Conclusion
Th9 cells are a novel described subtype of helper T
cells. It seems that Th9 cells promote allergic damages
in patients and experimental models. In addition, the
traces of Th9 cells have been found in certain micro-
bial infections, which require further investigation. We
have already provided several evidences on the role of
Th9 cells in IBD-induced pathologies. As we discussed
increased frequency of CD4+IL-9+ cells, so called Th9
cells are reported in animal models and patients with UC.
The changes in gene expression of IL-9 in biopsy speci-
mens of patients with IBD, the effects of such cytokines
on the expression of proteins that maintain tight inter-
cellular junctions and their potential role on immune tol-
erance in the gut merits further investigations. Although
the cited studies offered some answers to many questions
on the role of Th9 cells and IL-9 in the pathogenesis of
UC,many questions remained unanswered. Identification
of specific transcription factors involved in the differen-
tiation of these cells in inflammatory conditions such as
UC and in depth understanding of how expression of this
cytokine at gene and protein levels can bemanipulated are
essential for potential therapeutic strategies.
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